10402-33-2Relevant articles and documents
Eugenol derived immunomodulatory molecules against visceral leishmaniasis
Charan Raja, Mamilla R.,Velappan, Anand Babu,Chellappan, Davidraj,Debnath, Joy,Kar Mahapatra, Santanu
, p. 503 - 518 (2017/08/22)
Visceral leishmaniasis (VL) is a life threatening infectious disease caused by Leishmania donovani. It leads to the severe immune suppression in the host defense system. Higher cytotoxicity, rigorous side effects and lower therapeutic indexes (TI) of current antileishmanial drugs have created a necessity to develop new molecules with better antileishmanial activity and high TI value. In this study, we have synthesized 36 derivatives of eugenol and screened them for their activity against promastigote and amastigote forms of L. donovani. Among the synthesized derivatives, comp.35 showed better antileishmanial activity against extra cellular promastigotes (IC50- 20.13 ± 0.91 μM) and intracellular amastigotes (EC50-4.25 ± 0.26 μM). The TI value (82.24 ± 3.77) was found to improve by 10–13 fold compared to Amphotericin B and Miltefosine respectively. Treatment with comp.35 (5 μg/ml) enhanced the nitric oxide (NO) generation, iNOS2 mRNA expression (～8 folds increase) and decreased the arginase-1 activity (～4 folds) in L. donovani infected peritoneal macrophages. Comp.35 had also increased the IL-12 (～6 folds) and decreased the IL-10 (～3 folds) mRNA expression and release in vitro. Results of in vivo studies revealed that comp.35 treatment at 25 mg/kg body weight efficiently cleared the hepatic and splenic parasite burden with enhanced Th1 response in L. donovani infected BALB/c mice. Hence, this study clearly represents comp.35, as an immunomodulatory molecule, can induce host protective immune response against visceral leishmaniasis through enhanced NO generation and Th1 response, which are essentials against this deadly disease.
Antimicrobial and cytotoxic evaluation of eugenol derivatives
Martins, Rosiane Mastelari,Farias, Marília D’ Avila,Nedel, Fernanda,de Pereira, Claudio M. P.,Lencina, Claiton,Lund, Rafael Guerra
, p. 2360 - 2367 (2016/10/25)
Eugenol is the major phenolic component of clove essential oil and it has been used in medical and dental practice for its properties like analgesic, local anesthetic, and antioxidant. It is known that eugenol can denature proteins and react with cell membrane phospholipids changing their permeability and inhibiting a great number of Gram-negative and Gram-positive bacteria as well as different types of yeast. Eugenol has ever demonstrated antimicrobial properties; thus, the search for the optimization through structural changes appears to be interesting for the development of new antimicrobials. This study aimed to evaluate the antimicrobial activity and cytotoxic characteristics of eugenol analogs. From natural eugenol, 14 derivatives were obtained by typical acylation and alkylation. Their antimicrobial activity was evaluated by the broth microdilution method. The compounds were assessed against Staphylococcus aureus ATCC 19095, Enterococcus faecalis ATCC 4083, Escherichia coli ATCC29214, Pseudomonas aeruginosa ATCC 9027, Candida albicans ATCC 62342 and the following clinical isolates from the human oral cavity: C. albicans (3), C. parapsilosis C. glabrata C. lipolytica, and C. famata. Cytotoxicity against mouse embryonic fibroblast (NIH/3T3) cell line was evaluated by MTT colorimetric assay. The majority of compounds demonstrated significant antimicrobial activities. In general, the compounds presented very low or no cytotoxicity, with an inhibitory ratio lower than 50 % against NIH/3T3 cell line.
Eugenol derivatives as potential anti-oxidants: Is phenolic hydroxyl necessary to obtain an effect?
D'Avila Farias, Marilia,Oliveira, Pathise Souto,Dutra, Filipe S. Pereira,Fernandes, Thiely Jacobsen,De Pereira, Claudio M. P.,De Oliveira, Simone Quintana,Stefanello, Francieli Moro,Lencina, Claiton Leonetti,Barschak, Alethea Gatto
, p. 733 - 746 (2014/05/06)
Objectives Eugenol, obtained from clove oil (Eugenia caryophyllata), possess several biological activities. It is anti-inflammatory, analgesic, anaesthesic, antipyretic, antiplatelet, anti-anaphylactic, anticonvulsant, anti-oxidant, antibacterial, antidepressant, antifungal and antiviral. The anti-oxidant activity of eugenol have already been proven. From this perspective testing, a series of planned structural derivatives of eugenol were screened to perform structural optimization and consequent increase of the potency of these biological activities. Methods In an attempt to increase structural variability, 16 compounds were synthesized by acylation and alkylation of the phenolic hydroxyl group. Anti-oxidant activity capacity was based on the capture of DPPH radical (2,2-diphenyl-1-picryl-hydrazyl), ABTS radical 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid), measure of TBARS (thiobarbituric acid-reactive species), total sulfhydryl and carbonyl content (eugenol derivatives final concentrations range from 50 to 200 μm). Key findings Four derivatives presented an efficient concentration to decrease 50% of the DPPH radical (EC50) 100 μm, which has a good potential as a free-radical scavenger. Three of these compounds also showed reduction of ABTS radical. Eugenol derivatives presenting alkyl or aryl (alkylic or arylic) groups substituting hydroxyl 1 of eugenol were effective in reducing lipid peroxidation, protein oxidative damage by carbonyl formation and increase total thiol content in cerebral cortex homogenates. In liver, the eugenol derivatives evaluated had no effect. Conclusions Our results suggest that these molecules are promising anti-oxidants agents.
